Patent 7323300 was granted and assigned to ONCOTECH, INC. on January, 2008 by the United States Patent and Trademark Office.
The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a plurality of genes that are differentially expressed in chemotherapeutic drug resistant and drug sensitive tumor cells.